Randomized Study Demonstrating That Octreotide Fluid Crystal Provides Sustained Octreotide Bioavailability and Similar IGF-1 Suppression to Octreotide LAR (Sandostatin LAR) in Healthy Volunteers

Trial Profile

Randomized Study Demonstrating That Octreotide Fluid Crystal Provides Sustained Octreotide Bioavailability and Similar IGF-1 Suppression to Octreotide LAR (Sandostatin LAR) in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2015

At a glance

  • Drugs Octreotide (Primary) ; Octreotide
  • Indications Acromegaly; Carcinoid tumour; Diarrhoea; Intestinal obstruction; Neuroendocrine tumours; Polycystic liver disease; Prostate cancer; Thymoma
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 23 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top